A Single-center, Prospective, Exploratory Clinical Study

Inclusion criteria

• Newly diagnosed acute lymphoblastic leukemia (ALL) confirmed by bone marrow morphology, immunophenotyping, cytogenetics, and molecular biology according to the WHO 2022 classification criteria.
• Age ≥ 18 years, male or female.
• Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0-2.
• Life expectancy ≥ 3 months.
• Males and females of childbearing potential who agree to use effective contraceptive measures.
• Adequate organ function as defined by the following laboratory parameters:

Total bilirubin ≤ 1.5 × upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 × ULN; Serum creatinine < 1.5 × ULN; Serum amylase ≤ 1.5 × ULN; Creatine kinase-MB (CK-MB) ≤ 2 × ULN.

• Cardiac ejection fraction > 45% as determined by multigated acquisition (MUGA) scan.
• Voluntary participation in this clinical trial, with an understanding of the study procedures and the ability to provide written informed consent.

Exclusion criteria

• Diagnosis of mixed-phenotype acute leukemia (MPAL) or Burkitt lymphoma/leukemia according to the WHO 2008 classification criteria for tumors of hematopoietic and lymphoid tissues.
• Concurrent severe and/or uncontrolled underlying diseases, including but not limited to: other malignancies requiring concurrent treatment, acute or chronic hepatitis, severe pancreatic or renal disease, or other life-threatening underlying conditions; presence of severe active infections (e.g., sepsis, active tuberculosis, uncontrolled pneumonia, etc.).
• Pregnant or lactating women.
• Positive test for anti-HIV antibodies.
• Psychiatric disorders that may interfere with the patient's ability to complete the study treatment or provide informed consent.
• Any condition deemed by the investigator to make the patient unsuitable for enrollment.
• Inability to swallow capsules or tablets, or presence of gastrointestinal disorders significantly affecting gastrointestinal function and/or inhibiting small intestinal absorption (including malabsorption syndrome, small bowel resection, or poorly controlled inflammatory bowel disease).
• Known hypersensitivity to the study drug or any of its excipients.